American Association for Cancer Research
can-22-0554_supplemental_figure_1_suppsf1.pptx (529.2 kB)

Supplementary Figure from Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer

Download (529.2 kB)
posted on 2023-03-31, 05:24 authored by Viswam S. Nair, Angela Bik-Yu Hui, Jacob J. Chabon, Mohammad S. Esfahani, Henning Stehr, Barzin Y. Nabet, Li Zhou, Aadel A. Chaudhuri, Jalen Benson, Kelsey Ayers, Harmeet Bedi, Meghan Ramsey, Ryan Van Wert, Sanja Antic, Natalie Lui, Leah Backhus, Mark Berry, Arthur W. Sung, Pierre P. Massion, Joseph B. Shrager, Ash A. Alizadeh, Maximilian Diehn
Supplementary Figure from Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer


Fred Hutchinson Cancer Research Center


NIH Director's New Innovator Award Program




Genomic profiling of bronchoalveolar lavage (BAL) samples may be useful for tumor profiling and diagnosis in the clinic. Here, we compared tumor-derived mutations detected in BAL samples from subjects with non–small cell lung cancer (NSCLC) to those detected in matched plasma samples. Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq) was used to genotype DNA purified from BAL, plasma, and tumor samples from patients with NSCLC. The characteristics of cell-free DNA (cfDNA) isolated from BAL fluid were first characterized to optimize the technical approach. Somatic mutations identified in tumor were then compared with those identified in BAL and plasma, and the potential of BAL cfDNA analysis to distinguish lung cancer patients from risk-matched controls was explored. In total, 200 biofluid and tumor samples from 38 cases and 21 controls undergoing BAL for lung cancer evaluation were profiled. More tumor variants were identified in BAL cfDNA than plasma cfDNA in all stages (P < 0.001) and in stage I to II disease only. Four of 21 controls harbored low levels of cancer-associated driver mutations in BAL cfDNA [mean variant allele frequency (VAF) = 0.5%], suggesting the presence of somatic mutations in nonmalignant airway cells. Finally, using a Random Forest model with leave-one-out cross-validation, an exploratory BAL genomic classifier identified lung cancer with 69% sensitivity and 100% specificity in this cohort and detected more cancers than BAL cytology. Detecting tumor-derived mutations by targeted sequencing of BAL cfDNA is technically feasible and appears to be more sensitive than plasma profiling. Further studies are required to define optimal diagnostic applications and clinical utility. Hybrid-capture, targeted deep sequencing of lung cancer mutational burden in cell-free BAL fluid identifies more tumor-derived mutations with increased allele frequencies compared with plasma cell-free DNA.See related commentary by Rolfo et al., p. 2826

Usage metrics

    Cancer Research





    Ref. manager